BURLINGTON, Vt. — Prolytix said it has expanded its thrombosis and hemostasis testing capabilities through the acquisition of 60 validated assays from Hemostasis Reference Laboratory, a move the company said creates an end-to-end analytical services offering for biopharmaceutical sponsors.
The U.S.-based bioanalytical and protein characterization services provider said the assays were previously owned by HRL, a global reference laboratory known for its specialization in thrombosis and hemostasis testing. Prolytix said the acquisition strengthens its ability to support research, clinical, and regulated testing programs.
The company also said it has been awarded a Clinical Laboratory Improvement Amendments Certificate of Compliance, following an inspection that cited no deficiencies.
“This marks an exciting step forward as we continue expanding our capabilities to support GLP, GCP, and CLIA-compliant work within a dedicated laboratory space,” said Ryan Dorfman, chief operating officer of Prolytix. “The recent award of our CLIA Certificate of Compliance—accompanied by an inspection report citing no deficiencies—underscores the quality and rigor of our operations. With the addition of these assays, we significantly enhance our clinical and translational testing capacity, further strengthening Prolytix as a leader in hemostasis.”
Prolytix said the combination of its expertise in protein science with HRL’s experience in clinical and specialty coagulation testing will provide sponsors with a more integrated continuum of services. These capabilities span sample collection, research reagents, release and stability testing of protein therapeutics, and advanced bioanalytical testing.
“This is a natural and exciting fit,” said Joanne McGrath, manager of laboratory services at HRL. “Our teams share a deep commitment to scientific integrity and advancing the field, and will now be able to provide a more comprehensive solution that supports biopharmaceutical companies developing novel therapies in thrombosis, coagulation disorders, and hematologic disease.”
